Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses

Breast Carcinoma Clinical Trial

Official title:

Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03185871
• Other study ID #: UW16141
• Secondary ID: P30CA0145202017-
• Status: Withdrawn
• Phase: Phase 2
• Start date: September 20, 2017
• Est. completion date: October 10, 2018

Study information

• Verified date: October 2018
• Source: University of Wisconsin, Madison
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overall purpose of this study is to assess whether celecoxib can reduce the change in collagen alignment and inflammatory response in the tumor tissue of primary breast cancer patients with invasive breast carcinoma after 2 weeks of oral intake.

Description:

Advances in early detection techniques and improvement in systemic treatment of early stage breast cancer have led to a small decline in overall breast cancer mortality in the last 20 years. New advances will require understanding of breast cancer biology at the molecular level. Inhibition of COX-2 and its analysis of effect in breast cancer tumor microenvironment provide one such fruitful therapeutic target. Tumor microenvironment is poorly understood in breast cancer research. Despite new drugs being developed to treat breast cancer and tested in clinical trials, it is rarely possible to assess how the drug is affecting the breast cancer cells at a molecular level. The use of collagen properties such as alignment and deposition will allow giving a faster diagnosis of breast cancer status and seeing how celecoxib with respect to collagen can change the tumor microenvironment in human tissue. This window trial provides a way to look at cancer and stromal cells before and after celecoxib intake to see if the drug is actively working. If we can do this before and after a patient has surgery, and see how the tumor microenvironment responds, then the physician could pick a better suited adjuvant treatment for this patient after surgical intervention that would improve their overall survival rate.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 10, 2018
• Est. primary completion date: October 10, 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Participants must have biopsy proven invasive breast carcinoma stages T1cN0 to T3N0, ER or PR positive with tumors greater than 1cm without lymph node spread.

• Participants must have a mammographic breast composition category (density) of c or d.

• Participants must be willing to participate and provide signed informed consent.

• Participants must have no immediate requirements for chemotherapy, radiotherapy or hormonal therapy.

• Participants must be willing to discontinue any use of NSAIDs like aspirin or ibuprofen until the tumor is removed

• Participants cannot be taking the following medications because of major pharmacokinetic interactions with celecoxib while being enrolled in the study: Abciximab, Argatroban, Bivalirudin, Cilostazol, Dabigatran, Etexilate, Dipyridamole, Fondaparinux, Heparin, Lepirudin, Pemetrexed, Protein C, Rivaroxaban, Sibutramine, Ticlopidine, Tirofiban, Vilazodone and Warfarin.

• Participants should pass MRI screening questionnaire

Exclusion Criteria:

• Prior history of cancer, neo-adjuvant chemotherapy and radiation therapy

• No daily NSAIDs intake within the past 4 weeks. Intermittent non-daily NSAIDs is allowed under PI discretion.

• Current or prior systemic use of corticosteroids in the past month.

• Participants with history of hypertension, congestive heart failure, edema, stroke or other cardiac disease or condition.

• Participants with type 2 diabetes, documented stomach ulcers and pulmonary embolism.

• Participants with aspirin or other NSAIDs-induced asthma or hypersensitivity reaction, sulfonamide allergy

• Participants who are currently pregnant

• Participants with known human immunodeficiency virus (HIV) infection, hepatitis B carrier state or with clinical evidence of hepatitis B.

• Participants who are not able to understand or provide written informed consent.

• Participants with standard contraindications to non-contrast MRI will be excluded, including claustrophobia and metallic implants incompatible with MRI.

• Participants whose girth exceeds the bore of the MRI scanner.

• Participants requiring conscious sedation for MR imaging.

Related Conditions & MeSH terms

• Breast Carcinoma
• Breast Neoplasms
• Carcinoma

Intervention

Drug:
• Celecoxib
Celecoxib is the only COX-2 inhibitor currently approved by the FDA to be used in the United States. Recently, it has been shown that celecoxib prevents sporadic colorectal adenomas and there are more clinical trials evaluating the use of celecoxib in combination with chemotherapy regimens in breast cancer settings. Celebrex® oral capsules that will be used in this study contain 200 mg of celecoxib, in combination with inactive ingredients that include the following components: croscarmellose sodium, edible inks, gelatin, lactose monohydrate, magnesium stearate, povidone and sodium lauryl sulfate.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
University of Wisconsin, Madison	National Cancer Institute (NCI)

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in collagen	To determine change of collagen structure and proliferation in response to celecoxib intake in the tumor microenvironment.	Up to 6 weeks
Secondary	Change in correlation of collagen alignment and COX-2 expression	To evaluate correlation among collagen alignment and COX-2 expression before and after celecoxib intake.	Up to 6 weeks
Secondary	Changes in Syndecan-1	To analyze Syndecan-1 expression levels as stromal response biomarkers.	Up to 6 weeks
Secondary	Changes in CD68	To analyze CD68 expression levels as stromal response biomarkers.	Up to 6 weeks
Secondary	Changes in CD163	To analyze CD163 expression levels as stromal response biomarkers.	Up to 6 weeks
Secondary	Changes in neutrophil elastase	To analyze neutrophil elastase expression levels as stromal response biomarkers.	Up to 6 weeks
Secondary	Changes in vimentin	To analyze vimentin expression levels as stromal response biomarkers.	Up to 6 weeks
Secondary	Changes in a-SMA	To analyze a-SMA expression levels as stromal response biomarkers.	Up to 6 weeks
Secondary	Changes in Ki67	To analyze Ki67 expression levels as stromal response biomarkers.	Up to 6 weeks
Secondary	Changes in tissue cytokines in dense breast tissue	To discover tissue cytokines present in dense breast tissue that are altered in response to celecoxib.	Up to 6 weeks
Secondary	Number of subjects with adverse events associated with celecoxib	To evaluate any adverse events associated with the 2-week intake of 200mg celecoxib twice a day.	Up to 6 weeks
Secondary	Changes in collagen due to relationship of amount/percentage of fibroglandular tissue	To determine if changes in collagen structure and proliferation in response to celecoxib differ by the amount and/or percentage of fibroglandular tissue, measured quantitatively using MRI.	Up to 6 weeks

External Links

•   University of Wisconsin Carbone Cancer Center Homepage